326 related articles for article (PubMed ID: 24215406)
1. Certolizumab pegol in axial spondyloarthritis.
Song IH; Rudwaleit M
Expert Rev Clin Immunol; 2013 Dec; 9(12):1161-72. PubMed ID: 24215406
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
Callhoff J; Sieper J; Weiß A; Zink A; Listing J
Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
[TBL] [Abstract][Full Text] [Related]
3. Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis.
Spadaro A; Scarno A; Carboni A; Perrotta FM; Catalano C; Lubrano E; Valesini G
Reumatismo; 2013 Jul; 65(3):134-7. PubMed ID: 23884030
[TBL] [Abstract][Full Text] [Related]
4. Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis.
Dhillon S
Drugs; 2014 Jun; 74(9):999-1016. PubMed ID: 24919863
[TBL] [Abstract][Full Text] [Related]
5. Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial.
Sieper J; Landewé R; Rudwaleit M; van der Heijde D; Dougados M; Mease PJ; Braun J; Deodhar A; Kivitz A; Walsh J; Hoepken B; Nurminen T; Maksymowych WP
Arthritis Rheumatol; 2015 Mar; 67(3):668-77. PubMed ID: 25470228
[TBL] [Abstract][Full Text] [Related]
6. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
[TBL] [Abstract][Full Text] [Related]
7. Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi.
Malaviya AN; Kalyani A; Rawat R; Gogia SB
Int J Rheum Dis; 2015 Sep; 18(7):736-41. PubMed ID: 26172961
[TBL] [Abstract][Full Text] [Related]
8. Biologic therapies for spondyloarthritis: what is new?
Baraliakos X; Braun J
Curr Rheumatol Rep; 2012 Oct; 14(5):422-7. PubMed ID: 22855297
[TBL] [Abstract][Full Text] [Related]
9. Local infliximab injection of sacroiliac joints in non-radiographic axial spondyloarthritis: Impact on clinical and magnetic resonance imaging parameters of disease activity.
Soliman E; El-Tantawi G; Matrawy K; Aldawoudy A; Naguib A
Mod Rheumatol; 2015 May; 25(3):421-6. PubMed ID: 25401227
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety and cost per responder of biologics in the treatment of non-radiographic axial spondyloarthritis.
Olivieri I; Fanizza C; Gilio M; Ravasio R
Clin Exp Rheumatol; 2016; 34(5):935-940. PubMed ID: 27385374
[TBL] [Abstract][Full Text] [Related]
11. Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial.
Song IH; Weiß A; Hermann KG; Haibel H; Althoff CE; Poddubnyy D; Listing J; Lange E; Freundlich B; Rudwaleit M; Sieper J
Ann Rheum Dis; 2013 Jun; 72(6):823-5. PubMed ID: 23172749
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis.
Braun J; Baraliakos X; Heldmann F; Kiltz U
Expert Opin Investig Drugs; 2014 May; 23(5):647-59. PubMed ID: 24654630
[TBL] [Abstract][Full Text] [Related]
13. Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.
Wallman JK; Kapetanovic MC; Petersson IF; Geborek P; Kristensen LE
Arthritis Res Ther; 2015 Dec; 17():378. PubMed ID: 26703005
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.
Landewé R; Braun J; Deodhar A; Dougados M; Maksymowych WP; Mease PJ; Reveille JD; Rudwaleit M; van der Heijde D; Stach C; Hoepken B; Fichtner A; Coteur G; de Longueville M; Sieper J
Ann Rheum Dis; 2014 Jan; 73(1):39-47. PubMed ID: 24013647
[TBL] [Abstract][Full Text] [Related]
15. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
Smith LS; Nelson M; Dolder CR
Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
[TBL] [Abstract][Full Text] [Related]
16. New evidence on the management of spondyloarthritis.
Sieper J; Poddubnyy D
Nat Rev Rheumatol; 2016 May; 12(5):282-95. PubMed ID: 27052489
[TBL] [Abstract][Full Text] [Related]
17. Certolizumab pegol for treating axial spondyloarthritis.
Desmarais J; Beier S; Deodhar A
Expert Opin Biol Ther; 2016 Aug; 16(8):1059-64. PubMed ID: 27366922
[TBL] [Abstract][Full Text] [Related]
18. Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study.
Lubrano E; Perrotta FM; Marchesoni A; D'Angelo S; Ramonda R; Addimanda O; Olivieri I; Punzi L; Salvarani C
J Rheumatol; 2015 Feb; 42(2):258-63. PubMed ID: 25512483
[TBL] [Abstract][Full Text] [Related]
19. Certolizumab pegol for the management of Crohn's disease in adults.
Rivkin A
Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).
Sieper J; van der Heijde D; Dougados M; Mease PJ; Maksymowych WP; Brown MA; Arora V; Pangan AL
Ann Rheum Dis; 2013 Jun; 72(6):815-22. PubMed ID: 22772328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
